(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Warming winters lead to more nitrate pollution in the drinking water near farms - 2Amid growing bipartisan scrutiny of Pete Hegseth, Trump says he 'wouldn't have wanted … a second strike' on alleged Venezuelan drug boat survivors
- 3Netanyahu on Gush Etzion terror attack: 'We will complete war on all fronts'
- 4These HGTV stars made a pledge to keep their kids off smartphones. Here's how it's going.
- 5Obamacare enrollment declines as US subsidies expire
- Hundreds are quarantined in South Carolina as measles spreads in 2 US outbreaks
- Vote in favor of Your Number one BWM Vehicles
- 6 Top Computer game Control center
- 6 Popular Men's Aromas On the planet
- Netanyahu vows to ‘return Negev to Israel,’ pledges settlement growth during visit
- Flu is rising rapidly, driven by a new variant. Here's what to know
- Former hostage Eitan Mor on Hamas: ‘They will not give up until the last Israeli is gone'
- Germany ready to assist Syria's reconstruction, says foreign minister
- The best ice packs for coolers of 2026, tested and reviewed
